Geoffrey Fourqurean posted a piece on neuropathic pain. I asked: Would the drug leronlimab have an effect on this condition?
Like
like
1
Reply
1 reply
1 Comment on James Mitchell’s comment
17 impressions
View Geoffrey Fourqurean’s graphic link
Geoffrey Fourqurean
Author
Neuroscientist, Returned Peace Corps Volunteer, Polyglot, poet, Alumnus: AstraZeneca, GlaxoSmithKline, Neurocrine Biosciences, ex-Gilead, Chief Consultant, Patient Advocate, Biotech Industry Analyst, ESMO Member, Author
1d
James Mitchell Great question, James — and one that comes up often when discussing CCR5 biology. While I can’t speak to any specific drug, I can speak to the underlying mechanism.
Neuropathic pain is increasingly understood as a neuro-immune communication disorder, not just a neuronal one. CCR5 sits directly at that crossroads — regulating inflammatory signaling, glial activation, and the trafficking of immune cells into neural tissues. So any approach that modulates CCR5 has a clear mechanistic rationale for potentially influencing the inflammatory component of neuropathic pain.
At this time, no CCR5-modulating therapy is approved for neuropathic pain, so discussions remain mechanistic rather than clinical. Ultimately, dedicated clinical validation would be required to determine whether CCR5 modulation translates into real therapeutic benefit. The scientific rationale is strong — the question now is how the biology performs when tested directly.
Happy to discuss CCR5 pathways further — it’s a rapidly evolving and fascinating area of neuro-immunology.
Like
like
1
Reply
1 reply
1 Comment on James Mitchell’s comment
17 impressions
View Geoffrey Fourqurean’s graphic link
Geoffrey Fourqurean
Author
Neuroscientist, Returned Peace Corps Volunteer, Polyglot, poet, Alumnus: AstraZeneca, GlaxoSmithKline, Neurocrine Biosciences, ex-Gilead, Chief Consultant, Patient Advocate, Biotech Industry Analyst, ESMO Member, Author
1d
James Mitchell Great question, James — and one that comes up often when discussing CCR5 biology. While I can’t speak to any specific drug, I can speak to the underlying mechanism.
Neuropathic pain is increasingly understood as a neuro-immune communication disorder, not just a neuronal one. CCR5 sits directly at that crossroads — regulating inflammatory signaling, glial activation, and the trafficking of immune cells into neural tissues. So any approach that modulates CCR5 has a clear mechanistic rationale for potentially influencing the inflammatory component of neuropathic pain.
At this time, no CCR5-modulating therapy is approved for neuropathic pain, so discussions remain mechanistic rather than clinical. Ultimately, dedicated clinical validation would be required to determine whether CCR5 modulation translates into real therapeutic benefit. The scientific rationale is strong — the question now is how the biology performs when tested directly.
Happy to discuss CCR5 pathways further — it’s a rapidly evolving and fascinating area of neuro-immunology.
6
